Needham reiterated coverage of RxSight with a rating of Buy and set a new price target of $54.00 from $75.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/29/2024 | $72.00 | Buy | Jefferies |
| 8/20/2024 | $54.00 → $66.00 | Buy | Needham |
| 8/6/2024 | $75.00 → $54.00 | Buy | Needham |
| 5/7/2024 | $61.00 → $72.00 | Buy | BTIG Research |
| 12/13/2023 | $31.00 → $42.00 | Equal Weight → Overweight | Wells Fargo |
| 12/12/2023 | $40.00 | Buy | Stifel |
| 12/4/2023 | $36.00 | Overweight | Morgan Stanley |
| 4/13/2023 | $23.00 | Outperform | Oppenheimer |
10-Q - RxSight, Inc. (0001111485) (Filer)
8-K - RxSight, Inc. (0001111485) (Filer)
10-Q - RxSight, Inc. (0001111485) (Filer)
Jefferies initiated coverage of RxSight with a rating of Buy and set a new price target of $72.00
Needham reiterated coverage of RxSight with a rating of Buy and set a new price target of $66.00 from $54.00 previously
Needham reiterated coverage of RxSight with a rating of Buy and set a new price target of $54.00 from $75.00 previously
4 - RxSight, Inc. (0001111485) (Issuer)
4 - RxSight, Inc. (0001111485) (Issuer)
4 - RxSight, Inc. (0001111485) (Issuer)
ALISO VIEJO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended September 30, 2024. Key Quarterly Highlights Reported third quarter 2024 revenue of $35.3 million, an increase of 59% compared to the third quarter of 2023, reflecting: The sale of 24,554 Light Adjustable Lenses (LAL™/LAL+™), representing an 80% increase in procedure volume compared to the third quarter of 2023; andThe sale of 78 Light Delivery Devices (LDD™s), representing a 18% increase in unit sales compared to
ALISO VIEJO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the third quarter of 2024 after the market close on Thursday, November 7, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (888) 596-4144 or (646) 968-2525, and enter the conference code: 7406253. The call will also be broadcast live in listen-only mode via a link on the company's investor re
ALISO VIEJO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced its plans to participate in two upcoming healthcare conferences in September. Morgan Stanley 22nd Annual Global Healthcare Conference- Fireside Chat: Wednesday, September 4, 2024, at 9:15 a.m. ET in New York City, NY Wells Fargo 2024 Healthcare Conference- Fireside Chat: Thursday, September 5, 2024, at 3:45 p.m. ET in Boston, MA Interested parties may access live and archived webcasts of these events at https://investors.rxsight.com/. About RxSight, Inc. R
4 - RxSight, Inc. (0001111485) (Issuer)
4 - RxSight, Inc. (0001111485) (Issuer)
4 - RxSight, Inc. (0001111485) (Issuer)
SC 13G/A - RxSight, Inc. (0001111485) (Subject)
SC 13G/A - RxSight, Inc. (0001111485) (Subject)
SC 13G/A - RxSight, Inc. (0001111485) (Subject)
ALISO VIEJO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended September 30, 2024. Key Quarterly Highlights Reported third quarter 2024 revenue of $35.3 million, an increase of 59% compared to the third quarter of 2023, reflecting: The sale of 24,554 Light Adjustable Lenses (LAL™/LAL+™), representing an 80% increase in procedure volume compared to the third quarter of 2023; andThe sale of 78 Light Delivery Devices (LDD™s), representing a 18% increase in unit sales compared to
ALISO VIEJO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the third quarter of 2024 after the market close on Thursday, November 7, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (888) 596-4144 or (646) 968-2525, and enter the conference code: 7406253. The call will also be broadcast live in listen-only mode via a link on the company's investor re
ALISO VIEJO, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the second quarter of 2024 after the market close on Monday, August 5, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call please register here. While not required, it is recommended that participants join ten minutes prior to the event start time to ensure the necessary audio applicati
Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting
ALISO VIEJO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced the appointment of Tamara R. Fountain, M.D. and Shweta Singh Maniar to its Board of Directors. "We are very excited to continue to strengthen the RxSight Board of Directors with the additions of Dr. Fountain and Ms. Maniar. Their diverse healthcare leadership experience will support the strategic advancement of the company through its next chapter of growth," said J. Andy Corley, Chair of the Board of Directors. "We look forward to their respective contributions as the RxSight® Lig
Johnson & Johnson (NYSE:JNJ) was one of the worst-performing Dow Jones Industrial Average stocks in the first half of 2024. Investors and analysts will be looking for the company to show progress from a mixed first quarter when second-quarter financial results are reported Wednesday, July 17. Earnings Estimates: Analysts expect Johnson & Johnson to report second-quarter revenue of $22.31 billion, according to data from Benzinga Pro. The company reported revenue of $25.53 billion in last year's second quarter, meaning analysts see a revenue decline on a year-over-year basis. Johnson & Johnson has beaten revenue estimates in six of the past 10 quarters and four of the last five quarters.
7 analysts have shared their evaluations of RxSight (NASDAQ:RXST) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 3 2 0 0 0 Analysts have recently evaluated RxSight and provided 12-month price targets. The average target is $71.14, accompanied by a high estimate of $75.00 and a low estimate of $68.00. Marking an increase
BTIG analyst Ryan Zimmerman maintains RxSight (NASDAQ:RXST) with a Buy and raises the price target from $72 to $73.